Built by precision-medicine operators, scientists, and clinical laboratory leaders.
Phenomics Health brings together clinical laboratory operations, pharmacogenomics, pharmacometabolomics, informatics, data science, and company-building experience to make medication response more predictable.
One team across science, lab operations, data, and commercialization.
Medication response is a multi-signal problem. The Phenomics team reflects that, combining clinical testing, translational science, informatics, and enterprise healthcare workflows.
Clinical laboratory foundation
High-complexity testing capabilities that support precision prescribing and medication exposure workflows.
Precision medicine science
Pharmacogenomics, pharmacometabolomics, and response biology that anchor the platform’s clinical logic.
Data and intelligence layer
Multi-source patient data, evidence, and AI-enabled workflows built around auditable response phenotypes.
Enterprise deployment
Clinical, payor, provider, and life-sciences programs designed for practical adoption and measurable value.
Leadership
Experienced operators and scientific leaders building the medication-response intelligence platform.
Daniel Jasewicz
LinkedInCompany leadership, precision-medicine strategy, and medication-response intelligence
Daniel Jasewicz leads Phenomics Health’s strategy, commercialization, partnerships, and product direction. He brings experience across precision medicine, translational research, clinical operations, biotechnology, and health technology development, with prior roles spanning global clinical trial execution, preclinical research, program management, and precision-medicine operations. His background includes work with IQVIA Biotech, Regeneron, and Charles River Laboratories. At Phenomics, Daniel focuses on building practical medication-response intelligence solutions that connect laboratory science, clinical data, and AI-enabled decision support for clinicians, payors, and strategic partners.
Gerry Higgins
LinkedInScientific strategy across pharmacogenomics, medication response biology, and translational evidence
Gerry Higgins leads the scientific strategy behind Phenomics Health’s medication-response intelligence platform. His work is grounded in pharmacogenomics, computational biology, systems medicine, and the use of large-scale genomic, omics, and clinical datasets to better understand individual variation in drug response. He has contributed to research at the intersection of GWAS, PheWAS, omics atlases, deep learning, patient stratification, and pharmacophenomics, with a focus on moving precision prescribing beyond static genetic markers toward richer models of medication response. At Phenomics, Gerry helps translate complex biology into clinically meaningful evidence, platform logic, and auditable workflows for therapy selection, monitoring, and optimization.
Wenbing Chen
LinkedInClinical laboratory leadership, quality systems, and high-complexity testing operations
Wenbing Chen leads the clinical laboratory foundation supporting Phenomics Health’s precision-medicine programs. He brings deep experience in high-complexity laboratory operations, clinical testing oversight, quality systems, assay performance, and regulated laboratory workflows. As Laboratory Director, Wenbing helps ensure that Phenomics’ pharmacogenomics, medication exposure, and related testing programs are grounded in rigorous laboratory standards and operational discipline. His leadership anchors the company’s ability to connect advanced testing capabilities with reliable, clinically usable medication-response intelligence.
Scientific and company foundation
Founding leadership supporting the company’s precision-medicine, computational, and translational foundation.
James S. Burns
James S. Burns has more than 30 years of executive experience across pharmaceutical, biotechnology, diagnostic, venture capital, and private equity organizations. As a founder of Phenomics Health, he helped establish the company’s precision-medicine and commercialization foundation, bringing operating experience from leadership roles at Assurex Health, EntreMed, MedPointe Pharmaceuticals, Osiris Therapeutics, HealthCare Ventures, Becton Dickinson, and Booz Allen Hamilton.
Brian D. Athey
Brian D. Athey, Ph.D., is the Michael A. Savageau Collegiate Professor and Founding Chair of Computational Medicine and Bioinformatics at the University of Michigan Medical School. As co-founder of Phenomics Health, he brings more than 30 years of leadership in biomedical informatics, AI, pharmacogenomics, and medication-response phenotyping to the company’s mission of connecting multi-source patient data with next-generation pharmacogenomics and medication-response intelligence.
Built for clinical credibility, not generic AI positioning.
Phenomics Health combines laboratory capabilities, medication exposure measurement, pharmacogenomics, and AI-enabled response intelligence to support safer, more informed medication decisions.
Why the team matters
- Clinical laboratory operations anchor the testing and quality foundation.
- Scientific leadership connects PGx, PMx, exposure, and outcomes into medication-response logic.
- Data and technology capabilities translate multi-source signals into auditable workflows.
- Commercial and operating leadership focus the platform on deployable healthcare programs.
Launch a medication-response intelligence program.
Connect with Phenomics Health to discuss clinical decision support, medication-risk analytics, lab partnerships, peptide monitoring, and life-sciences research programs.